Phaseline

Companies › Diagonal Therapeutics

Diagonal Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Cardiovascular; next expected readout Nov 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DIAG723
Bispecific agonist monoclonal antibody targeting ALK-1 and BMPRII
ALK1, BMPR2Phase 1Hereditary Hemorrhagic TelangiectasiaNov 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07623525DIAG723Phase 1Hereditary Hemorrhagic TelangiectasiaCardiovascularNov 2027

Targets

ALK1 (1) BMPR2 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.